Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Study of ARRY-334543 in Patients With Advanced Cancer

NCT00278902
completedphase_1

A Study of ARRY-334543 in Patients With Advanced Cancer

NCT00637702
completedphase_1

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

NCT00833326
completedphase_1

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

NCT00710736
completedphase_1

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

NCT00862524

Clinical Trials (5)

Showing 5 of 5 trials
NCT00278902Phase 1

A Study of ARRY-334543 in Patients With Advanced Cancer

Completed
NCT00637702Phase 1

A Study of ARRY-334543 in Patients With Advanced Cancer

Completed
NCT00833326Phase 1

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

Completed
NCT00710736Phase 1

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

Completed
NCT00862524Phase 1

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5